Myeloma Trial, Recruiting (NCT06245629)

Myeloma Trial, Recruiting NCT06245629 Sponsor: Uppsala University Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06245629 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with multiple myeloma that came back for the first time after having a stem cell transplant using your own stem cells (called an autologous stem cell transplant, or ASCT).
You received a second autologous stem cell transplant (using your own stem cells) as part of your treatment for this relapse, carried out at UUH (Uppsala University Hospital).
Your preparation treatment (conditioning) before that second transplant used either a combination of bortezomib, bendamustine, and melphalan, or high-dose melphalan on its own.

Who may not be able to join:

You received two stem cell transplants in a row (called a tandem transplant) as part of your first or second round of treatment.
You received a stem cell transplant using someone else's stem cells (called an allogeneic transplant) as part of your first or second round of treatment.
Your medical records do not contain enough information to meet the required data requirements — this includes having records of key dates (such as transplant dates and treatment start dates), hospital records from your second transplant, at least one follow-up appointment, and records of when your myeloma came back and what treatment followed (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Honar Cherif, MD, PhD, Uppsala University

Phone: +4623492000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06245629

Sponsor: Uppsala University

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: +4623492000

More information: https://clinicaltrials.gov/study/NCT06245629

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with multiple myeloma that came back for the first time after having a stem cell transplant using your own stem cells (called an autologous stem cell transplant, or ASCT).
You received a second autologous stem cell transplant (using your own stem cells) as part of your treatment for this relapse, carried out at UUH (Uppsala University Hospital).
Your preparation treatment (conditioning) before that second transplant used either a combination of bortezomib, bendamustine, and melphalan, or high-dose melphalan on its own.

Who may not be able to join:

You received two stem cell transplants in a row (called a tandem transplant) as part of your first or second round of treatment.
You received a stem cell transplant using someone else's stem cells (called an allogeneic transplant) as part of your first or second round of treatment.
Your medical records do not contain enough information to meet the required data requirements — this includes having records of key dates (such as transplant dates and treatment start dates), hospital records from your second transplant, at least one follow-up appointment, and records of when your myeloma came back and what treatment followed (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Uppsala University

Registry

ClinicalTrials.gov

Start date

24 November 2024

Est. completion

31 March 2025

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Mean difference in time to next treatment (TNT) after ASCT1 and ASCT2 for each individual patient

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov